The authors of a pharmacoeconomic study comparing bezlotoxumab plus oral vancomycin, oral vancomycin alone, and fidaxomicin found that oral vancomycin alone was the most cost-effective regimen to treat the first recurrence of Clostridium difficile infection.
Article Limit Reached
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content